PL3266456T3 - Skojarzenia liposomalnego irinotekanu, 5-fu i leukoworyny do leczenia nowotworu trzustki - Google Patents
Skojarzenia liposomalnego irinotekanu, 5-fu i leukoworyny do leczenia nowotworu trzustkiInfo
- Publication number
- PL3266456T3 PL3266456T3 PL17169098T PL17169098T PL3266456T3 PL 3266456 T3 PL3266456 T3 PL 3266456T3 PL 17169098 T PL17169098 T PL 17169098T PL 17169098 T PL17169098 T PL 17169098T PL 3266456 T3 PL3266456 T3 PL 3266456T3
- Authority
- PL
- Poland
- Prior art keywords
- leucovorin
- combinations
- treatment
- pancreatic cancer
- liposomal irinotecan
- Prior art date
Links
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title 1
- 235000008191 folinic acid Nutrition 0.000 title 1
- 239000011672 folinic acid Substances 0.000 title 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title 1
- 229960004768 irinotecan Drugs 0.000 title 1
- 229960001691 leucovorin Drugs 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261659211P | 2012-06-13 | 2012-06-13 | |
US201361784382P | 2013-03-14 | 2013-03-14 | |
EP17169098.5A EP3266456B1 (en) | 2012-06-13 | 2013-06-12 | Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer |
EP13731230.2A EP2861210B1 (en) | 2012-06-13 | 2013-06-12 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
PCT/US2013/045495 WO2013188586A1 (en) | 2012-06-13 | 2013-06-12 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3266456T3 true PL3266456T3 (pl) | 2021-11-29 |
Family
ID=48692681
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13731230T PL2861210T3 (pl) | 2012-06-13 | 2013-06-12 | Sposoby leczenia raka trzustki z zastosowaniem terapii skojarzonych zawierających liposomalny irinotekan |
PL17169098T PL3266456T3 (pl) | 2012-06-13 | 2013-06-12 | Skojarzenia liposomalnego irinotekanu, 5-fu i leukoworyny do leczenia nowotworu trzustki |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13731230T PL2861210T3 (pl) | 2012-06-13 | 2013-06-12 | Sposoby leczenia raka trzustki z zastosowaniem terapii skojarzonych zawierających liposomalny irinotekan |
Country Status (22)
Country | Link |
---|---|
US (10) | US9452162B2 (pl) |
EP (3) | EP3919048A1 (pl) |
JP (3) | JP6310911B2 (pl) |
KR (3) | KR20190107010A (pl) |
CN (2) | CN104717961A (pl) |
AU (3) | AU2013202947B2 (pl) |
BR (1) | BR112014031088A8 (pl) |
CA (1) | CA2875824C (pl) |
DK (2) | DK2861210T3 (pl) |
ES (2) | ES2880089T3 (pl) |
HK (2) | HK1209627A1 (pl) |
IL (3) | IL235937B (pl) |
IN (1) | IN2014DN11099A (pl) |
MX (1) | MX2014015391A (pl) |
NZ (1) | NZ702469A (pl) |
PL (2) | PL2861210T3 (pl) |
PT (2) | PT2861210T (pl) |
RU (1) | RU2663450C2 (pl) |
SI (2) | SI2861210T1 (pl) |
TW (3) | TWI729492B (pl) |
WO (1) | WO2013188586A1 (pl) |
ZA (1) | ZA201408804B (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2967961T3 (es) | 2004-05-03 | 2024-05-06 | Ipsen Biopharm Ltd | Liposomas útiles en la administración de fármacos |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2015206667B2 (en) | 2014-01-14 | 2020-05-14 | Nektar Therapeutics | Combination-based treatment method |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
EP3229802A1 (en) * | 2014-12-09 | 2017-10-18 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
WO2016168451A1 (en) * | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
PT3337467T (pt) | 2015-08-20 | 2021-01-25 | Ipsen Biopharm Ltd | Terapia de combinação utilizando irinotecano lipossomal e um inibidor parp para tratamento do cancro |
SG10201913077QA (en) * | 2015-08-21 | 2020-02-27 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
JP2018527377A (ja) | 2015-09-16 | 2018-09-20 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 癌の処置におけるトポイソメラーゼ−i阻害剤と免疫療法との組み合わせ |
BR122021024957B1 (pt) | 2015-10-16 | 2023-12-12 | Ipsen Biopharm Ltd | Processos de produção de uma composição de irinotecano lipossômico estabilizado em armazenamento |
WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
BR112018072988A2 (pt) * | 2016-05-18 | 2019-04-09 | Ipsen Biopharm Ltd. | irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula |
AU2017354903B2 (en) * | 2016-11-02 | 2023-04-13 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
JP7542529B2 (ja) * | 2018-10-17 | 2024-08-30 | バイオラインアールエックス・リミテッド | 転移性膵臓腺癌の処置 |
WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
EP3911353A1 (en) * | 2019-01-17 | 2021-11-24 | BioLineRx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
US11286344B2 (en) | 2020-01-10 | 2022-03-29 | Tyndall Formulation Services, LLC | Polymer excipients for drug delivery applications |
EP4087545A1 (en) | 2020-01-10 | 2022-11-16 | R-Pharm US Operating LLC | Compositions of ixabepilone |
WO2021142020A1 (en) * | 2020-01-10 | 2021-07-15 | Tyndall Formulation Services, LLC | Formulations of sn-38 with poly(amino acid) block polymers |
KR20240082379A (ko) * | 2021-10-03 | 2024-06-10 | 시스트이뮨, 인코포레이티드 | 암 치료 방법 및 이의 약제학적 조성물 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2628659A (en) * | 1951-01-17 | 1953-02-17 | Charles R Carpenter | Convertible furniture article |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
AU4990397A (en) | 1996-10-22 | 1998-05-15 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
US6355268B1 (en) | 1998-09-16 | 2002-03-12 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
AU2869901A (en) | 2000-02-04 | 2001-08-14 | Lipoxen Technologies Limited | Liposomes |
US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
DK1286671T3 (da) | 2000-05-15 | 2006-07-17 | Celgene Corp | Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan |
IL153676A0 (en) | 2000-06-30 | 2003-07-06 | Inex Pharmaceuticals Corp | Liposomal pharmaceutical compositions |
TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
WO2002076428A1 (en) | 2001-03-26 | 2002-10-03 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
AU2002328945A1 (en) | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Methods for improved treatment of cancer with irinotecan based on mrp1 |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
ITBO20010610A1 (it) | 2001-10-05 | 2003-04-05 | Haworth S P A | Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo |
CA2752143C (en) | 2002-05-15 | 2014-09-23 | Sutter West Bay Hospitals | Delivery of nucleic acid-like compounds |
MXPA04011871A (es) | 2002-05-31 | 2005-07-26 | Transmolecular Inc | Quimioterapia en combinacion con clorotoxina. |
AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
ES2967961T3 (es) | 2004-05-03 | 2024-05-06 | Ipsen Biopharm Ltd | Liposomas útiles en la administración de fármacos |
GEP20094620B (en) | 2004-06-01 | 2009-02-25 | Yakult Honsha Kk | Irinotecan preparation |
JP2008501651A (ja) | 2004-06-03 | 2008-01-24 | エフ.ホフマン−ラ ロシュ アーゲー | イリノテカン(cpt−11)およびegfr阻害剤を用いた処置 |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
WO2007050784A2 (en) | 2005-10-25 | 2007-05-03 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
DK2338487T3 (da) | 2006-01-17 | 2013-12-09 | Abbvie Bahamas Ltd | Kombinationsterapi med PARP-inhibitorer |
AU2007227466B2 (en) | 2006-03-16 | 2011-11-17 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
KR101107911B1 (ko) * | 2006-11-30 | 2012-01-25 | 아크레이 가부시키가이샤 | Ugt1a1 유전자 증폭용 프라이머 셋트, 그것을 포함하는ugt1a1 유전자 증폭용 시약 및 그 용도 |
PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
JP2010540498A (ja) | 2007-09-28 | 2010-12-24 | ウニヴェルズィテーツシュピタール バーゼル | 癌の治療のための免疫リポソーム |
US20090123419A1 (en) | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
WO2009073869A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
JP2011515478A (ja) | 2008-03-25 | 2011-05-19 | シェーリング コーポレイション | 結腸直腸がんを処置または予防するための方法 |
US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
KR20110008086A (ko) | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
AU2008362109B2 (en) | 2008-09-26 | 2015-08-27 | Institut De Cancerologie De L'ouest | Individual 5-fluorouracile dose optimization in FOLFIRI treatment |
US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
CA2758856A1 (en) | 2009-05-01 | 2010-11-04 | Oncozyme Pharma Inc. | Pentamidine combinations for treating cancer |
PL2508170T3 (pl) | 2009-12-03 | 2015-12-31 | Jiangsu Hengrui Medicine Co | Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania |
NZ706745A (en) | 2010-06-04 | 2017-01-27 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
MX2013000779A (es) | 2010-07-19 | 2013-07-05 | Bipar Sciences Inc | Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales. |
MX349662B (es) | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
WO2012031293A1 (en) | 2010-09-03 | 2012-03-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of cancer |
CN103327983A (zh) | 2010-12-06 | 2013-09-25 | 梅里麦克制药股份有限公司 | 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药 |
WO2012079582A1 (en) | 2010-12-14 | 2012-06-21 | Technical University Of Denmark | Entrapment of radionuclides in nanoparticle compositions |
JP6054308B2 (ja) | 2011-02-15 | 2016-12-27 | メリマック ファーマシューティカルズ, インコーポレイテッドMerrimack Pharmaceuticals, Inc. | 核酸を細胞へ送達する組成物及び方法 |
DK2699602T3 (en) | 2011-04-19 | 2017-06-06 | Merrimack Pharmaceuticals Inc | BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES |
JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
US9511155B2 (en) | 2012-04-17 | 2016-12-06 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
WO2014113167A1 (en) | 2012-12-14 | 2014-07-24 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
DK2979700T3 (en) | 2013-03-27 | 2019-01-21 | Taiho Pharmaceutical Co Ltd | ANTITUMUM AGENT CONTAINING A LOW IRINOTECAN HYDROCHLORIDE HYDRATE |
EP3038600B1 (en) | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
US20160303264A1 (en) | 2013-10-23 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for non-invasive imaging and drug delivery |
EP3229802A1 (en) | 2014-12-09 | 2017-10-18 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
WO2016168451A1 (en) | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
PT3337467T (pt) | 2015-08-20 | 2021-01-25 | Ipsen Biopharm Ltd | Terapia de combinação utilizando irinotecano lipossomal e um inibidor parp para tratamento do cancro |
SG10201913077QA (en) | 2015-08-21 | 2020-02-27 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
BR122021024957B1 (pt) | 2015-10-16 | 2023-12-12 | Ipsen Biopharm Ltd | Processos de produção de uma composição de irinotecano lipossômico estabilizado em armazenamento |
US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
BR112018072988A2 (pt) | 2016-05-18 | 2019-04-09 | Ipsen Biopharm Ltd. | irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula |
AU2017354903B2 (en) | 2016-11-02 | 2023-04-13 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
-
2013
- 2013-04-08 AU AU2013202947A patent/AU2013202947B2/en active Active
- 2013-06-11 TW TW108132921A patent/TWI729492B/zh active
- 2013-06-11 TW TW107116721A patent/TW201831168A/zh unknown
- 2013-06-11 TW TW102120630A patent/TWI630924B/zh active
- 2013-06-12 KR KR1020197018996A patent/KR20190107010A/ko not_active Application Discontinuation
- 2013-06-12 CA CA2875824A patent/CA2875824C/en active Active
- 2013-06-12 EP EP21171689.9A patent/EP3919048A1/en active Pending
- 2013-06-12 CN CN201380036765.4A patent/CN104717961A/zh active Pending
- 2013-06-12 DK DK13731230.2T patent/DK2861210T3/en active
- 2013-06-12 AU AU2013274287A patent/AU2013274287B2/en active Active
- 2013-06-12 WO PCT/US2013/045495 patent/WO2013188586A1/en active Application Filing
- 2013-06-12 SI SI201330697T patent/SI2861210T1/sl unknown
- 2013-06-12 EP EP17169098.5A patent/EP3266456B1/en active Active
- 2013-06-12 DK DK17169098.5T patent/DK3266456T3/da active
- 2013-06-12 MX MX2014015391A patent/MX2014015391A/es active IP Right Grant
- 2013-06-12 PT PT137312302T patent/PT2861210T/pt unknown
- 2013-06-12 SI SI201331912T patent/SI3266456T1/sl unknown
- 2013-06-12 BR BR112014031088A patent/BR112014031088A8/pt not_active Application Discontinuation
- 2013-06-12 EP EP13731230.2A patent/EP2861210B1/en not_active Revoked
- 2013-06-12 PL PL13731230T patent/PL2861210T3/pl unknown
- 2013-06-12 ES ES17169098T patent/ES2880089T3/es active Active
- 2013-06-12 ES ES13731230.2T patent/ES2632915T3/es active Active
- 2013-06-12 US US14/406,776 patent/US9452162B2/en active Active
- 2013-06-12 NZ NZ702469A patent/NZ702469A/en unknown
- 2013-06-12 KR KR1020157000450A patent/KR101776808B1/ko active IP Right Grant
- 2013-06-12 PL PL17169098T patent/PL3266456T3/pl unknown
- 2013-06-12 IL IL235937A patent/IL235937B/en unknown
- 2013-06-12 IL IL294886A patent/IL294886A/en unknown
- 2013-06-12 KR KR1020177024678A patent/KR101997206B1/ko active IP Right Grant
- 2013-06-12 PT PT171690985T patent/PT3266456T/pt unknown
- 2013-06-12 IN IN11099DEN2014 patent/IN2014DN11099A/en unknown
- 2013-06-12 RU RU2015100529A patent/RU2663450C2/ru active
- 2013-06-12 JP JP2015517405A patent/JP6310911B2/ja active Active
- 2013-06-12 CN CN201910188153.6A patent/CN110051631A/zh active Pending
-
2014
- 2014-12-02 ZA ZA2014/08804A patent/ZA201408804B/en unknown
-
2015
- 2015-07-29 US US14/812,950 patent/US9339497B2/en active Active
- 2015-09-03 US US14/844,500 patent/US9364473B2/en active Active
- 2015-09-11 US US14/851,111 patent/US9492442B2/en active Active
- 2015-10-22 HK HK15110395.3A patent/HK1209627A1/xx not_active IP Right Cessation
-
2016
- 2016-03-03 US US15/059,640 patent/US20160228428A1/en not_active Abandoned
- 2016-11-02 US US15/341,377 patent/US20170065578A1/en not_active Abandoned
-
2017
- 2017-06-08 JP JP2017113465A patent/JP2017149783A/ja not_active Withdrawn
- 2017-07-18 US US15/652,513 patent/US20170368056A1/en not_active Abandoned
-
2018
- 2018-03-19 AU AU2018201942A patent/AU2018201942B2/en active Active
- 2018-06-19 US US16/012,351 patent/US10980795B2/en active Active
- 2018-07-04 HK HK18108641.6A patent/HK1248608A1/zh unknown
-
2019
- 2019-05-07 JP JP2019087488A patent/JP6857210B2/ja active Active
-
2021
- 2021-03-17 US US17/204,278 patent/US20220096458A1/en active Pending
-
2023
- 2023-07-20 IL IL304631A patent/IL304631A/en unknown
-
2024
- 2024-03-22 US US18/613,609 patent/US20240226090A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1248608A1 (zh) | 使用含脂質體伊立替康的組合療法治療胰腺癌的方法 | |
HRP20171474T1 (hr) | Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka | |
LT2861584T (lt) | Piridopirazino ir naftiridino dariniai, skirti vėžiui gydyti | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
EP2820423A4 (en) | MATERIALS AND METHOD FOR DIFFERENTIATED TREATMENT OF CANCER | |
EP2941421A4 (en) | COUMESTAN, COUMESTROL, COUMESTAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | |
GB2500588B (en) | Systems and methods of hyperthermal treatment | |
EP2897689A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALOPEZIA | |
IL239374B (en) | Preparations and methods for treating brain tumors | |
ZA201502009B (en) | Combinations of sglt2 inhibitors and antihypertensive drugs | |
ZA201504167B (en) | Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates | |
ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis | |
PT2892560T (pt) | Métodos e produtos para prevenção e/ou tratamento do cancro metastático | |
GB2507765B8 (en) | Substituted pyridine derivatives useful in the treatment of cancer | |
EP2870133A4 (en) | TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF | |
AP3759A (en) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same | |
IL239817A0 (en) | Comstan, Comstrol, their derivatives, processes for their production and their uses | |
AU2012903874A0 (en) | Methods and products for preventing and/or treating cancer | |
GB201222855D0 (en) | Lock Means and Method of Use Thereof |